Vericiguat therapy for three months significantly improved endothelial function in patients with HFrEF, increasing flow-mediated dilation from 15% to 19% (P=0.04).
Does vericiguat improve endothelial function assessed by flow-mediated dilation in patients with HFrEF and worsening heart failure?
Three months of vericiguat therapy is associated with improved endothelial function in patients with HFrEF and worsening heart failure.
Absolute Event Rate: 0% vs 0%
Background Vericiguat, a soluble guanylate cyclase stimulator, has been shown to be effective in improving the prognosis of patients with heart failure with reduced ejection fraction (HFrEF) and worsening heart failure. We sought to evaluate possible changes in endothelial function assessed by flow-mediated dilation (FMD) in patients with HFrEF treated with vericiguat. Results Improved FMD values were found after 3 months of therapy with vericiguat (19 ± 11 vs. 15 ± 10% FMD, P = 0.04). FMD variation at follow-up was inversely related to baseline FMD values ( r = –0.52, P = 0.001). Major findings Three months of therapy with vericiguat in patients with HFrEF and worsening heart failure were associated with improved endothelial function assessed by FMD.
Correale et al. (Tue,) reported a other. Vericiguat therapy for three months significantly improved endothelial function in patients with HFrEF, increasing flow-mediated dilation from 15% to 19% (P=0.04).